Sumitomo Mitsui DS Asset Management Company Ltd Has $2.29 Million Stake in Moderna, Inc. (NASDAQ:MRNA)

Sumitomo Mitsui DS Asset Management Company Ltd boosted its position in Moderna, Inc. (NASDAQ:MRNA) by 2.2% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 34,206 shares of the company’s stock after purchasing an additional 746 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Moderna were worth $2,286,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Ashton Thomas Private Wealth LLC acquired a new position in shares of Moderna in the second quarter valued at approximately $26,000. Cedar Wealth Management LLC grew its holdings in Moderna by 45.0% during the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after acquiring an additional 90 shares during the last quarter. Westside Investment Management Inc. acquired a new position in Moderna in the 1st quarter valued at approximately $32,000. Family Firm Inc. acquired a new position in Moderna in the 2nd quarter valued at approximately $33,000. Finally, Bank & Trust Co bought a new position in shares of Moderna during the second quarter valued at $36,000. 75.33% of the stock is currently owned by institutional investors.

Moderna Stock Performance

Shares of Moderna stock opened at $53.80 on Tuesday. The business has a 50-day simple moving average of $70.20 and a 200 day simple moving average of $104.25. Moderna, Inc. has a one year low of $53.05 and a one year high of $170.47. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.09 and a quick ratio of 3.92. The firm has a market capitalization of $20.62 billion, a price-to-earnings ratio of -3.43 and a beta of 1.66.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, beating the consensus estimate of ($3.47) by $0.14. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The firm had revenue of $241.00 million during the quarter, compared to the consensus estimate of $128.41 million. During the same quarter in the previous year, the company posted ($3.62) earnings per share. The company’s quarterly revenue was down 29.9% on a year-over-year basis. On average, research analysts anticipate that Moderna, Inc. will post -9.85 earnings per share for the current fiscal year.

Insider Buying and Selling at Moderna

In other news, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the transaction, the chief financial officer now directly owns 8,600 shares in the company, valued at $682,754. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CFO James M. Mock sold 1,321 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the transaction, the chief financial officer now owns 8,600 shares of the company’s stock, valued at approximately $682,754. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Noubar Afeyan sold 15,000 shares of Moderna stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $119.96, for a total value of $1,799,400.00. Following the transaction, the director now owns 2,224,015 shares of the company’s stock, valued at $266,792,839.40. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 33,184 shares of company stock worth $3,804,931. 15.70% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several analysts recently weighed in on MRNA shares. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research note on Friday, September 13th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $75.00 price target on shares of Moderna in a research report on Thursday, September 19th. William Blair restated a “market perform” rating on shares of Moderna in a research report on Thursday, June 27th. TD Cowen reduced their target price on Moderna from $70.00 to $60.00 and set a “hold” rating on the stock in a report on Friday, September 13th. Finally, Barclays lowered their price target on shares of Moderna from $155.00 to $125.00 and set an “overweight” rating for the company in a report on Monday, September 16th. Two analysts have rated the stock with a sell rating, fourteen have issued a hold rating and four have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $97.18.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.